Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia

Area of Science:

• Neuroscience
• Psychiatry
• Medical Imaging

Background:

• Psychiatric neuroimaging often relies on correlational data, limiting causal inference for brain-behavior relationships.
• Negative symptoms in schizophrenia, such as anhedonia and amotivation, are disabling and poorly responsive to current treatments.
• A robust brain network model is needed to understand and potentially treat these refractory symptoms.

Purpose of the Study:

• To identify a specific brain network associated with negative symptoms in schizophrenia.
• To empirically test if modulating this network can causally impact symptom severity.
• To investigate a novel network hypothesis for medication-refractory negative symptoms.

Main Methods:

• A resting-state functional connectivity analysis was performed on a cohort (N=44) to identify a network correlating with negative symptom severity.
• A second cohort (N=11) received transcranial magnetic stimulation (TMS) targeting the cerebellar midline for 5 days to modulate the identified network connectivity.
• Changes in network connectivity were assessed in relation to changes in negative symptom severity.

Main Results:

• A breakdown in connectivity within a dorsolateral prefrontal cortex-to-cerebellum network directly correlated with negative symptom severity.
• Modulation of this network's connectivity using TMS led to a significant amelioration of negative symptoms.
• A strong, statistically significant relationship was observed between functional connectivity changes and negative symptom improvement.

Conclusions:

• A connectivity deficit between the cerebellum and the right dorsolateral prefrontal cortex is implicated in the severity of negative symptoms in schizophrenia.
• Correction of this network breakdown via TMS ameliorates negative symptoms, supporting a novel network-based treatment approach.
• Network manipulation may establish causal links between neuroimaging markers and clinical outcomes, offering new therapeutic avenues for refractory symptoms.